Everything else has gone to the cloud, so why not your chemistry research too? 🥼 As this new blog post outlines, a cloud-native application opens up a world of possibilities for lab research. Integrate data from multiple devices, leverage #AI capabilities, and realize your research goals using readily available cloud services: http://ms.spr.ly/6044Yk62I
About us
Revvity Signals Software has more than three decades providing unrivaled support for scientific workflows. Our powerful solutions are used across R&D disciplines from drug discovery to specialty chemicals material development. Now under our comprehensive Signals Research Suite, our end-to-end SaaS solution integrates workflows across biology, chemistry and materials new product development to accelerate scientific innovation, and help scientists help each other. In addition, our robust solution, powered by TIBCO® Spotfire®, can revolutionize the clinical trial process. From our internationally recognized flagship ChemDraw® and E-Notebook applications, to our Signals Research Suite (Signals Notebook, Signals VitroVivo and Signals Inventa) to our exclusive TIBCO® Spotfire® partnership that brings scientific data analytics to visual life, no scientific company offers a wider range and more powerful suite of scientific solutions than Revvity Signals.
- Website
-
https://revvitysignals.com/
External link for Revvity Signals
- Industry
- Software Development
- Company size
- 5,001-10,000 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Public Company
Locations
-
Primary
940 Winter St
Waltham, Massachusetts 02451, US
Employees at Revvity Signals
Updates
-
Lots of energy and great discussions on the first day of #ChemUK! If you're in Birmingham this week, stop by Booth M62 to meet the #RevvitySignals team. We'd love to share more about how our solutions are accelerating research for research chemists and formulations scientists!
-
Wasted time and increased costs can delay clinical trial analytics. That's why we're introducing Signals Clinical, your solution to streamline clinical data management. Our #SaaS platform offers efficient data handling and processing, reducing manual tasks and allowing more time for strategic analysis: http://ms.spr.ly/6045YXlyD
-
How are you keeping pace with the evolving data management landscape? 📊 We hope you can join us on June 6 for a webinar on accelerating the path to database lock with #datascience! Gain insights from data managers navigating this shift and learn about the skills needed to thrive in this evolving environment: http://ms.spr.ly/6045YXwpD
-
What's your strategy in keeping up with new drug modalities? The field of #drugdiscovery is advancing at an unprecedented pace, and both new and established modalities must be continuously reexamined to uncover novel combinations and more effective treatments: http://ms.spr.ly/6043Ypn1L
-
The Copenhagen Seminar 2024, hosted by #RevvitySignals and LabTwin – Digital Lab Assistant, is next month and promises to be an informative event packed with industry updates and technology workflow support! Join us for discussions on scientific developments in drug discovery and lab efficiency: http://ms.spr.ly/6045YpVf9
-
In the dynamic landscape of emerging technologies, including #AI, what's on the horizon for #RevvitySignals? Our own David Gosalvez, PhD sheds light on our development process, highlighting the importance of partnerships with the scientific community. Read his blog post: http://ms.spr.ly/6045YpVsJ
-
Attention scientists in the #pharmaceutical and #industrialchemistry sectors! Our upcoming Connect webinar will explore how Signals Notebook revolutionizes formulation science workflows and can help you leverage science data for enhanced analytics. Join us: http://ms.spr.ly/6043YpujT
-
Revvity Signals reposted this
Linkedin Top Branding Voice 💡 | Helping Businesses Select Blue Ocean Move and Conducting Rapid Market Tests.
What Are the Main Challenges of Modern Clinical Trials? With a cumulative total of almost 478,000 globally registered trials from the year 2000 to 2023, and growing at around 10 per cent a year in the last five years, the pharmaceutical industry continues to invest in clinical trials as the gold-standard test of therapeutic safety and efficacy. In addition, as the world’s economies and populations move in new directions, the share of non-US trials has reached 54 per cent, a trend that is likely to continue, driven by demographics and epidemiology. As the pace accelerates, trial managers and clinicians face a significant challenge: the explosive growth of data volumes. To succeed in the future, clinical trials need to increase efficiency and better utilise clinical trial data to support informed clinical and operational decision-making. Read more about the challenges and opportunities facing modern clinical trials in this insightful article by Mark Weadon, Global Analytics Product Marketing Manager at Revvity Signals. Read the full article here https://t.ly/3A0Jc
-
💊 New drug modalities have rapidly grown since 2019 and were expected to account for 56% of the total pipeline by 2023. Is your software technology keeping pace? Learn more from our new article, 'Pioneering New Modalities for Therapeutic Leadership:' http://ms.spr.ly/6046YTSAq